相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation
Hiroaki Akamatsu et al.
ANTICANCER RESEARCH (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
Edward S. Kim et al.
FUTURE ONCOLOGY (2021)
A real-world study in advanced non-small cell lung cancer with de novo brain metastasis
Lei Lei et al.
JOURNAL OF CANCER (2021)
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan
Yao-Yu Hsieh et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Tianli Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Masayuki Takeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients
Niki Karachaliou et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Clinical utility of ramucirumab in non-small-cell lung cancer
Dipesh Uprety
BIOLOGICS-TARGETS & THERAPY (2019)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Maximilian Hochmair
TARGETED ONCOLOGY (2018)
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Po-Lan Su et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
L. Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Ramucirumab in the treatment of non-small cell lung cancer
Oscar Arrieta et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer
Consuelo Buttigliero et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)